Special, Surveys

Biotech execs predict big M&A deals ahead as mood shifts in wake of a 2018 hangover — Endpoints 100

It’s time once again to feel the pulse of the biotech industry. 

In our latest survey of the Endpoints 100 — a collection of biotech execs dominated by CEOs of largely small and medium-sized companies — we gathered 80 responses. And they reflected a common sense of belief in the industry’s financial strengths at the start of 2019, the need for drug pricing reform, a general acceptance — with some big caveats — for the need to attend #JPM20 and a reevaluation of the way biotech assets will be valued and sold in the year ahead.

We detected:

— A distinct surge of support for any changes in the drug pricing system we have now that would provide some added transparency for the public. The administration’s suggested end to rebates is generally popular.

— A pronounced level of caution over the hype we’re hearing regarding AI in drug discovery and development.

— A sense of duty accompanied by a deep-seated level of animosity regarding our annual migration to attend JPMorgan, topped by a layer of discontent when it comes to San Francisco sprinkled with a little gung-ho enthusiasm for limitless deal talks.

— A general sense of optimism for the year ahead, with a strong current of appreciation for access to capital and a major shift in sentiment regarding the E100’s evaluation of IPOs and biotech valuations even as M&A turns hot, hot, hot. The go-go days of 2018 are clearly over.

Who's next on the M&A list? There's no shortage of suggestions and plenty of forecasts that the Bristol-Myers/Celgene alliance won't work out.


In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 44,500+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,500+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Sr. Manager, Regulatory Affairs, CMC
CytomX Therapeutics San Francisco, CA
Marketing Associate - Demand Generation
Catalytic Data Science Charleston, SC
Associate Principal, Life Sciences Partnerships
Flatiron Health New York City or San Francisco

Visit Endpoints Careers ->